Wednesday 6 January 2021
Investor Ideas #Potcasts 513- #Cannabis News and #Stocks on the Move; (TSXV: $FLWR.V) (OTC: $MJNA) (OTCQB: $CTGL) (TSX: $AVCN.TO)
Investor Ideas #Potcasts 513- #Cannabis News and #Stocks on the Move; (TSXV: $FLWR.V) (OTC: $MJNA) (OTCQB: $CTGL) (TSX: $AVCN.TO)
Delta, Kelowna, BC, January 6, 2020 (Investorideas.com Newswire)
www.Investorideas.com, a global news source covering leading sectors including
marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/010621-StocksToWatch.mp3
Read this in full
at
https://www.investorideas.com/news/2021/cannabis-potcasts/01061FLWR-MJNA-CTGL-AVCN.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on
Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com "Potcast"
featuring cannabis news, stocks to watch as well as insights from thought
leaders and experts.
In
today’s podcast we will be looking at a few public company announcements.
North America’s first research and
development facility dedicated to advancing cannabis cultivation techniques and
systems has been completed by The Flowr
Corporation (TSXV: FLWR) and Hawthorne Canada Limited. Hawthorne is a subsidiary of the
Hawthorne Gardening Company division of The
Scotts Miracle-Gro Company (NYSE:SMG). Scotts Miracle-Gro is the world’s
leading marketer of branded consumer lawn and garden products and indoor growing
solutions. Flowr cultivates and sells premium cannabis to medical and adult-use
markets in Canada, Europe and Australia.
Located on Flowr’s cultivation
campus in Kelowna, British Columbia, Canada, the R&D Center includes
state-of-the-art laboratories, indoor grow suites, and training areas in a
single building. Flowr will test cultivation systems and techniques using
Hawthorne’s advanced lighting, fertilization and irrigation systems, growing
mediums, and research protocols. In addition, Flowr intends to focus its own
research on cannabis genetics and integrated growing systems in line with its
goal of delivering premium quality cannabis products through highly efficient
cultivation.
“We built Hawthorne to help
cultivators of all sizes grow quality plants with high levels of efficiency and
consistency. Completing the industry’s only dedicated R&D facility gives us
a distinct advantage. We will leverage Flowr’s cultivation expertise and our
technical capabilities into real world testing and results that will make a
difference to growers,” said Chris Hagedorn, SVP & General Manager of
Hawthorne Gardening. “We are proud of this collaboration with Flowr, a leading
international cannabis company, with extensive growing experience indoors, in
greenhouses and at-scale outdoors. Flowr is also one of a few companies that
have had experience growing diverse genetics in different countries. We believe
this experience will benefit our companies and the growers we serve.”
“The completion of the R&D
Center brings our work with Hawthorne fully to life and will help keep both
companies on the leading edge of cannabis cultivation for years to come,”
commented Lance Emanuel, President and Interim Chief Executive Officer of
Flowr. “Operationalizing the R&D Center is a major accomplishment for our
organization and strengthens our competitive advantage in cultivation. We
believe the long-term success of Flowr will be rooted in our ability to
maximize the cannabinoid and terpene expression of genetics without sacrificing
yield. The work we will do at the R&D Center will help us build upon the
success we’ve had producing high quality, premium cannabis like our
award-winning, flagship-strain BC Pink Kush beloved by budtenders and consumers
throughout Canada. Leveraging our work at the R&D Center will be imperative
to our eventual entry into the United States once federally permissible by
law.”
The R&D Center is the
centerpiece of a strategic R&D partnership formed by Flowr and Hawthorne in
March 2018. It brings two of the world’s leading experts together to be at the
forefront of cannabis cultivation. The operations will be led by Dr. Deron
Caplan, the first person in North America to earn a PhD focused on cannabis
cultivation and production. Dr. Caplan was awarded his doctorate by the
University of Guelph in August 2018 and is Flowr’s Director of Research and
Development. The R&D Center will be staffed by Flowr’s scientists, five of
whom have PhDs in various plant biology, plant genetics and plant biochemistry
disciplines. Hawthorne R&D will lead the research design and methodology.
All requisite licensing from Health
Canada has been obtained by Flowr and the expectation is that the R&D
Center will be operating at full capacity in Spring 2021. Research has already
begun conducting growing trials at scale using Hawthorne products.
Medical
Marijuana, Inc. (OTC: MJNA) announced that its subsidiary HempMeds® has
launched its first-ever products containing cannabigerol (CBG) and cannabinol
(CBN) as part of the Company’s recently updated brand strategy.
“When we founded HempMeds a decade
ago, we were helping to create the entire CBD category. Since then, CBD has
become the booming industry that we expected and acceptance for cannabinoids
has come an incredibly long way in the last few years,” said HempMeds®
Co-Founder Michelle Sides. “While our flagship RSHO products remain popular, we
recognized it was time to expand alongside the industry and broaden our offerings
as part of the company’s exciting new direction. We are confident that
consumers will be excited about our new CBG and CBN products.”
Each 12-ounce bottle of HempMeds®’
RSHO® Calm Support is formulated to promote overall relaxation with 300 mg of CBN,
2,000 mg of CBD and 300 mg of Piperine, naturally derived from black pepper, to
increase bioavailability.
For those looking for an additional
boost of focus, each 12-ounce bottle of RSHO® Focus Support offers 1,500 mg of
CBD, 1,500 mg of CBG and 300 mg of Piperine.
“It is amazing to think that there
are over 100 lesser-known minor cannabinoids in the cannabis plant, each with
its own potential benefits. With minor cannabinoids like CBG and CBN growing in
popularity, they will likely take over more and more of the expected $47.2
billion global cannabis market. We look forward to continuing to expand and
evolve our offerings in response to consumer demand, starting with these new
products,” said HempMeds® CEO Raul Elizalde.
On December 30, 2020, Cannovation
Center Israel Ltd. won Israeli Government Ministry of Economy grant to acquire
10,000 square meters (2.5 acres) of industrial land to build the Cannovation
Center Israel at the Biopharma Park in Yeruham.
The Cannovation Center Israel is a
unique platform that includes factories for the production of medical cannabis,
botanicals, CBD, hemp, supplements, food, and cosmetic products; laboratories
for quality assurance, research, development, and clinical trials; a logistics,
distribution, import and export center; business development strategy services.
Citrine
Global, Corp. (OTCQB: CTGL) operates in Israel through its
wholly owned subsidiary, CTGL - Citrine Global Israel Ltd. ("Citrine
Global Israel"), which focuses on Israeli technologies in the fields of
healthcare, wellness, foodtech and medical cannabis.
Cannovation Center Israel Ltd. is
60%-owned by Citrine Global Israel Ltd. and Citrine Global Group views the
establishment of the Cannovation Center Israel as a national project backed by
grants and support from the Israeli government and the Yeruham local council,
and is aiming to create an ecosystem and collaborations between companies,
entrepreneurs, universities and partners from Israel and around the world.
Ora Elharar Soffer, CEO, Citrine
Global Corp.: "We are proud to be the ones to establish the first
operational innovation center of its kind for cannabis in the Biopharma Park in
Yeruham with the support of the Israeli government and Yeruham Local Council
and take part in the realization of Tal Ohana's vision to turn Yeruham into the
capital of medical cannabis. The Cannovation Center Israel will provide a
comprehensive operational solution tailored to the requirements of the cannabis
and botanical industry and is an important milestone that combines production,
operations, technologies, and business development to leverage local and
international collaborations. According to our strategy, we plan to build
additional operational innovation centers working in this business model around
the world."
Tal Ohana, Mayor of Yeruham:
"We have been working with Ora Elharar Soffer and the Citrine Global Group
and welcome the establishment of the innovative Cannovation Center Israel in
the Biopharma Park in Yeruham. Our vision to turn Yeruham into the medical
cannabis capital, through the Green-Negev project which I have been leading in
the last few years, is becoming a reality. We receive support from the Israeli
government and leading companies and entrepreneurs. In the last year, we have
established a start-up incubator for cannabis technologies with the assistance
of the Innovation Authority and in partnership with the pharmaceutical company
Perrigo, which has a factory in Yeruham, and with Israeli Cannabis Company BOL.
The incubator is already active, and the expected volume of investments is NIS
150 million for the operation of the incubator in the coming years. In
addition, we received approval from the Ministry of Economy to allocate land
and support factories' construction, which includes a 30% return on investment
in the construction of the factory, a subsidized industrial area, reduced
corporate tax, subsidy for senior employees' salaries, and more."
Avicanna
Inc. (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company
focused on the development, manufacturing and commercialization of
plant-derived cannabinoid-based products, announced that the Company has entered into a
master services agreement with the University Health Network for projects to be
performed by Dr. Peter Carlen as the principal investigator related to
epilepsy. Additionally, the company has completed the technical transfer and
first pharmaceutical pilot production of its epilepsy drug candidate at Altea
Farmaceutica S.A. in Bogota, Colombia, a major step required for the final
preparation for its registration and commercialization in South America.
The epilepsy research collaboration
is lead by Dr. Peter Carlen, who is a Senior Scientist at the Krembil Research
Institute at UHN and a world-renowned researcher in the field of epilepsy. Dr.
Carlen's laboratory will be analyzing Avicanna's RHO Phyto and pharmaceutical
cannabinoid-based products for their efficacy in the treatment of seizures.
The partnership will also co-develop
a high throughput electrophysiological testing system for the evaluation of
multiple cannabinoid ratios and in combination with standard epileptic drugs.
In addition, the system will examine standard anti-seizure drugs for their
efficacy in the model and determine the potential synergistic value of
adjunctive cannabinoids, and cannabinoids as monotherapy in treating seizures
in this in vitro setting.
Dr. Peter Carlen commented: “The
Carlen lab is very pleased to research the relationships between the premium
medicinal cannabinoid products of Avicanna and their effects on epilepsy. Also,
in collaboration with Avicanna, we are developing a high-throughput platform to
assess these interactions. We think that medical cannabinoids will have a major
impact on brain health, particularly as we gain greater understanding of their
effects on brain function in health and disease.”
The services to be performed under
the Master Services Agreement will be provided on an exclusive basis and Dr.
Carlen's laboratory has agreed to not conduct testing on any formulations or
products similar to the Products for a period of two (2) years. All
intellectual property created under the Master Services Agreement will remain
the sole property of Avicanna. The research collaboration is further expanded
to include electrophysiological studies of medical cannabinoids on 3D human
cerebral organoids and neuroglial cultures with the support of a two-year
Mitacs Accelerate program grant.
Avicanna also completed its first
pharmaceutical level production of its first epilepsy drug candidate under GMP
and ICH guidelines which are necessary for sanitary drug registration. The
formulation developed by Avicanna includes active pharmaceutical ingredients
which are cannabinoids produced by Avicanna’s subsidiary Santa Marta Golden
Hemp S.A.S. The final GMP manufacturing took place at Avicanna’s exclusive
manufacturing partner’s, Altea’s, facility in Bogota, which is a Health Canada
and ANVISA (Brazil) approved GMP facility. The completion of this
pharmaceutical production now allows Avicanna to proceed with drug registrations
for epilepsy across several markets in South America including Colombia and
Brazil.
Aras Azadian, CEO of Avicanna,
commented: “We are pleased to demonstrate our dedication to world-class
research and to take this stride in our epilepsy research program with a
leading Canadian research institute and Dr. Carlen. This multi-level
partnership will help to further study our current medical cannabis and
pharmaceutical products, and will support the development and increase the
depth of our pharmaceutical pipeline. Additionally, the completion of our first
pharmaceutical production marks a milestone event in our drug development plans
and highlights our capabilities to scale our drug formulations from bench top
to industrial manufacturing.”
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks
and other ideas on our site using our list of top stock trading
apps including Robinhood, Acorn,
Stash and others.
To hear more Investorideas.com podcasts
visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock news column, Investor
Ideas Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but
otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. Contact management and IR of each
company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor
Ideas – news, articles, podcasts and stock
directory
Tuesday 5 January 2021
Monday 4 January 2021
Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 512 - 2020 Round Up
Investor Ideas #Potcasts,
#Cannabis News and #Stocks on the Move; Episode 512 - 2020 Round Up
Delta, Kelowna, BC, January 4, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/010421-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2021/cannabis-potcasts/01041Round-Up-2020.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we will be taking a quick look back at 2020 and the year’s main
highlights.
Sales Growth:
While COVID-19 has had a significantly
negative impact on most industries this year, the cannabis sector has seen
substantial sales growth month over month as the year has progressed. This can
be attributed to many factors related to COVID measures as well as to the
success and growth of the industry itself.
One
of the first contributing factors that helped sales growth this year was the
very different place the entire industry was at the start of 2020 when compared
to years previous. Supply issues were a massive factor contributing to lower
sales in 2018 and 2019 in Canada and in the US, multi-state operators were
still in the process and gaining the footing and building out their
infrastructure. Looking at the start of 2020 we saw in Canada that many of the
large scale producers who struggled in the first two years finally hit their
stride as far as product supply levels and quality and consistency of their
products. We also began to see the development of a premium bud segment in the
industry through partnerships with smaller niche cultivators and the Cannabis
2.0 products that had been in the wing for months finally started hitting
retail shelves. The retail development
within Canada was also in a much more stable and built out position starting
in 2020 than in other years with private retail stores in BC and Ontario, the
two most populous provinces, seeing massive growth.
Image courtesy of: MJBIZ Daily
With
the industry being in a much better starting position entering 2020, the next
big factor to impact sales was obviously COVID-19 and lockdowns.
In
Canada with so many people stuck at home due to lockdown procedures and mahy
receiving government aid checks from being out of the work, we saw a massive
spike in Cannabis usage and sales as many who were on the fence socially about
this substance in years previous changed their perception.
This
was also massively aided by Cannabis businesses being deemed essential in both
the US and Canada as well as other parts of the world where legal cannabis
operations are in place. This change from Illegal to essential brought many new
consumers to the market and has helped remove some of the long standing stigma
surrounding the industry.
These
contributing factors which aided to sales gave many companies in the industry
the much needed revenue boost they had been waiting for and allowed many
companies the time and financial resources to begin expansion and innovation.
Industry Innovation:
Increased sales and
revenues in many ways helped stabilize what was previously a very unstable
industry, which allowed many to use the time to innovate and expand.
We
saw a plethora of Cannabis 2.0 products that had been stuck in development hell
for months finally begin hitting shelves and as more products hit retail stores
we saw competitors continue to innovate and adapt their products to consumers
needs as the year progressed.
Not
only did many companies innovate with regards to their products but we also saw
many retailers build out their online capabilities and begin offering delivery
and cubside services, where regulators allowed, which again helped increase
their customer share and overall sales.
Now
most of the US and Canadian cannabis retail sector offers online sales,
delivery or curbside pickup as well as touchless transactions and interactive
menus, all features that had been slowly developing over the last two years but
suddenly saw a massive jump in 2020 due to the necessity for innovation COVID
created.
This
also translated to the underserved medical community who saw massive growth in
Telemedicine usage globally and in medical cannabis countries, there were
serious adjustments to the overall medical industry which now allows for easier
access to cannabis medication, delivery and curbside pick up options,
telemedicine prescription and information access as well as a massive growth in
product selection and inventory.
Continued
Legalization and Social Acceptance:
While I had already mentioned the
massive social change created from Cannabis businesses being deemed essential
this year, there was also another huge shift in the US, as well as globally
towards cannabis reform policy and general drug reform policy.
This
year saw many new states in the US vote for cannabis reform such as New Jersey,
Montanna, Arizona and South Dakota, which all voted in favor of cannabis
reform. We also saw states like Oregan set new drug policy precedent in the US
by voting in favor of decriminalizing virtually all drugs and legalizing
medicinal psilocybin.
On
a global scale we saw more countries in South America extend or improve their
cannabis drug policies in favour of import and export opportunities and
increased medical availability. One of the largest holdouts as well as probably
one of the largest potential markets, Mexico looks to have some sort of medical
cannabis program in place in 2021, though regulatory progress has been slow so
far. Even in South East Asia we have seen a growing leniency towards CBD
products with some countries beginning the process of implementing a medical
cannabis program, again most likely in 2021 or 2022.
In
the EU, while we haven’t seen any major changes to the legal landscape, 2020
did help continue to build out the EU infrastructure for the medical and CBD
industry and we have seen massive growth when it comes to import and export
markets.
What’s Next?
Looking ahead at 2021 and beyond
there's a lot of hype and expectation surrounding the cannabis industry once
again. One of the best things to come out of 2020 has been increased investor
confidence and interest in this industry that saw a large investment slump
since legalization in Canada in 2018. Many of the the industries largest
companies are now trading back up at their regular prices and many smaller
companies have had their best trading year to date.
This increase in investor and consumer
confidence in the industry should help push some of the last needed
advancements in regulation and industry reform to boost the cannabis industry
into the same social and societal acceptance of alcohol, if not allowing it
surpass alcohol due to alcohol's many negative health impacts.
Looking at the US in 2021 we can
definitely expect more speculation and hype surrounding the idea of either Safe
Banking Access or decriminalization of cannabis, at least one of these outcomes
seems likely this year. We have seen many companies in both the US and Canada
preparing for the merging of markets and with the implementation of at least
Safe Banking Access a floodgate of investor capital becomes available to US
based cannabis companies.
Looking at Canada, there is
expectation of regulatory reform surrounding delivery access in some provinces,
private retail expansion as well a hopeful reevaluation of dosage and packaging
restrictions, all of which would greatly benefit overall industry.
Looking globally and at the industry
as a whole, South American expansion of both medical and recreational markets
seems inevitable as does expansion of the EU recreational market. There is a
lot of excitement surrounding South East Asian markets establishing medical
markets though this looks to be further out than 2021, though CBD products are
very much in play. Finally we have seen a lot of infrastructure build out in
Israel and parts of Africa, both of which could have massive impacts on the
global pricing of Cannabis and CBD products as well as the import and export
markets.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade
these stocks and other ideas on our site using our list of top stock trading apps including
Robinhood, Acorn, Stash and others.
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and
equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly
regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor
Ideas – news, articles, podcasts and
stock directory
Subscribe to:
Posts (Atom)
-
Investorideas.com - Cannabis Stock News: TransCanna (CSE: TCAN) Product Ranks in Leafly's Top Cannabis Strains List
-
Investorideas.com - CBD Stock News: InnoCan Pharma (CSE: INNO) Announces the Successful Completion of an Independent Clinical Study Demonstr...
-
New #Cannabis Stocks Added to Investor Ideas; (TSX: $FAF.V) (CSE: $STIL.C) (CSE: $ORCD.C) (CSE: $VREO.C) (CSE: $PUMP.C) (OTC: $NUGL) ...